12:00 AM
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IPI-926: Phase II started

Infinity began the double-blind, placebo-controlled Phase II portion of an international Phase Ib/II trial to evaluate oral IPI-926 in combination with Gemzar gemcitabine. The Phase II portion will evaluate once-daily 160 mg IPI-926, which...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >